UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report: June 07, 2004
CYTOMEDIX, INC.
(Exact name of registrant as it appears in its charter)
Delaware 0-28443 23-3011702
(State or other jurisdiction (Commission File Number) (IRS Employer
of incorporation Indentification No.)
1523 South Bowman Rd., Suite A,
Little Rock, Arkansas 72211
(Address of principal executive offices and zip code)
(501) 219-2111
(Registrant's telephone number, including area code)
ITEM 5. OTHER EVENTS AND REGULATION FD DISCLOSURE
On June 7, 2004, Cytomedix, Inc. issued the attached press release
announcing that its board of directors had appointed Mr. Mark T. McLoughlin to
fill a vacancy on the company's board of directors. The press release is filed
as Exhibit 99.1 and incorporated herein by reference.
ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS.
(c) Exhibits. The following Exhibit is filed with this Current Report on Form
8-K:
Exhibit No. Description
- ----------- -----------
Exhibit 99.1 Press Release of Cytomedix, Inc., dated June 7, 2004.
SIGNATURES
Pursuant to the requirements of the Securities Act of 1934, the registrant
has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
CYTOMEDIX, INC.
By: /s/ William Allender
----------------------------------
William Allender
Chief Financial Officer
Date: June 7, 2004